Legal Analysis<\/title> \n<\/head><\/p>\n<h5>Analysis of EU Legislation<\/h5>\n<h3>1. Anti-Dumping Duty on Steel Track Shoes from China<\/h3>\nThe Commission has imposed a definitive anti-dumping duty of 62.5% on steel track shoes originating from China. This decision follows an investigation that confirmed Chinese companies were dumping these products on the EU market, harming local industry. Certain specialized steel track shoes are excluded from this duty. For track chains containing these shoes, the duty applies to the value of the steel track shoes, provided they make up at least 31% of the chain’s total value. Provisional duties already collected will now be finalized.<\/p>\n<h3>2. Joint Clinical Assessments for Medical Devices<\/h3>\nThis regulation lays out the detailed procedures for how EU member states and the European Commission will exchange information during joint clinical assessments (JCAs) of medical devices. It covers the preparation, updating, and participation in these assessments, including templates for the assessments themselves. The health technology developers will be informed about the selection of their devices for JCA, and what information they need to provide.<\/p>\n<h3>3. Authorisation of ‘B. Braun Medical Propanol Family’ Biocidal Products<\/h3>\nThe European Commission has granted Union authorization for the biocidal product family ‘B. Braun Medical Propanol Family’, valid from November 2025 to October 2035. The authorization covers product-types 1, 2 and 4, which include human hygiene, disinfectants not for direct human\/animal use, and food\/feed area disinfection. The active substances in this product family are propan-1-ol and propan-2-ol. The authorisation holder must conduct a long-term storage stability test and submit the results to the Agency by September 2026.<\/p>\n<h3>4. Amendments Regarding Quillaia Extract (E 999) as a Food Additive<\/h3>\nThe EU has updated the rules for quillaia extract, a food additive. The regulation now allows its use as an emulsifier in flavorings and solid\/liquid food supplements (excluding those for infants and young children). The specifications for quillaia extract have also been revised with updated one that include a more detailed definition, CAS number, minimum saponin content, reduced limits for toxic elements (arsenic, lead, mercury), and new limits for cadmium and calcium oxalate, as well as microbiological criteria. Existing products lawfully on the market can still be sold until stocks run out or until their expiration date.<\/p>\n<h3>5. EU-Ukraine Association Committee Decision on Trade<\/h3>\nDecision No. 3\/2025 of the EU-Ukraine Association Committee in Trade Configuration introduces Annex I-E to the agreement. The goal is to further enhance trade relations, considering Ukraine’s ongoing integration into the EU internal market and its accession negotiations, by reducing and eliminating customs duties between the European Union and Ukraine. For 2025, tariff rate quotas will be seven-twelfths of the quantities listed in Annex I-E. Ukraine must align its legislation with EU legal acts listed in Appendix C by December 31, 2028, and to report annually on its progress.<\/p>\n<h3>Review of each of legal acts published today:<\/strong><\/h3>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2081\"><\/p>\n<h3>Commission Implementing Regulation (EU) 2025\/2081 of 17\u00a0October 2025 imposing a definitive anti-dumping duty and definitively collecting the provisional duty imposed on imports of steel track shoes originating in the People\u2019s Republic of China<\/strong><\/h3>\n<\/a><\/p>\nThis is a Commission Implementing Regulation imposing a definitive anti-dumping duty on imports of steel track shoes originating in the People\u2019s Republic of China. This regulation follows an anti-dumping investigation initiated after a complaint lodged by Duferco Travi e Profilati S.p.A. The Commission determined that steel track shoes from China were being dumped on the EU market, causing material injury to the Union industry. As a result, the regulation imposes a definitive anti-dumping duty of 62.5% on all imports of steel track shoes originating in China, with certain exceptions.<\/p>\nThe regulation is structured as follows: It begins by outlining the procedure, including the initiation of the investigation, registration of imports, and imposition of provisional measures. It then defines the product under investigation, the product concerned, and the like product. The regulation details the dumping calculation, including the determination of normal value, export price, and dumping margin. It assesses the injury to the Union industry, examining Union consumption, import volumes and prices, and the economic situation of the Union industry. The regulation also considers causation, the level of measures, and the Union interest. Finally, it sets out the definitive anti-dumping measures, including the duty rate and provisions for assembled products. Compared to the provisional regulation, this implementing regulation excludes certain cast steel track shoes from the scope of the anti-dumping duty and provides more detailed rules for the application of the duty to steel track shoes assembled in track chains.<\/p>\nSeveral provisions of this act are particularly important. First, the regulation imposes a definitive anti-dumping duty of 62.5% on imports of steel track shoes originating in China. Second, certain steel track shoes exceeding specific dimensions and lacking grousers are excluded from the duty. Third, for track chains containing steel track shoes, the regulation specifies that the anti-dumping duty applies to the value of the steel track shoes, with a minimum threshold of 31% of the track chain’s value. Finally, the regulation confirms that amounts secured by way of provisional anti-dumping duties will be definitively collected.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2086\"><\/p>\n<h3>Commission Implementing Regulation (EU) 2025\/2086 of 17\u00a0October 2025 laying down, pursuant to Regulation (EU)\u00a02021\/2282 on health technology assessment, procedural rules for the interaction during, exchange of information on, and participation in, the preparation and update of joint clinical assessments of medical devices and in vitro diagnostic medical devices at Union level, as well as templates for those joint clinical assessments<\/strong><\/h3>\n<\/a><\/p>\nHere’s a breakdown of the Commission Implementing Regulation (EU) 2025\/2086:<\/p>\n**1. Essence of the Act:**<\/p>\nThis regulation establishes the detailed procedures for how the Member States and the European Commission will interact and exchange information when conducting joint clinical assessments (JCAs) of medical devices and in vitro diagnostic medical devices within the European Union. It outlines the steps for preparing, updating, and participating in these joint assessments, including templates for the assessments themselves. The goal is to streamline the process, avoid duplication of effort, and ensure that medical devices are evaluated consistently across the EU.<\/p>\n**2. Structure and Main Provisions:**<\/p>\nThe regulation is structured around the procedural aspects of joint clinical assessments for medical devices, focusing on interactions and information exchange. Key provisions include:<\/p>\n* **Information Flow:** It details how the Coordination Group for Health Technology Assessment, the European Commission (acting as the secretariat), notified bodies, expert panels, health technology developers, and individual experts will exchange information during the JCA process. \n* **Health Technology Developer Involvement:** It specifies when and how health technology developers are informed about the selection of their devices for JCA, and what information they need to provide. \n* **Expert Selection:** It outlines the process for selecting individual experts to participate in JCAs, emphasizing the need for diverse expertise and conflict of interest management. \n* **Assessment Scope and Dossier Submission:** It sets deadlines and procedures for finalizing the assessment scope (the specific questions the JCA will address) and for health technology developers to submit the necessary data and documentation. \n* **Report Templates:** It includes templates for the dossiers that health technology developers must submit, as well as for the joint clinical assessment reports and summary reports. \n* **Timelines:** It establishes specific deadlines for various steps in the JCA process, from finalizing the assessment scope to completing the draft reports. \n* **Re-initiation and Updates:** It provides rules for re-initiating a JCA if it was initially discontinued, and for updating a JCA when new evidence becomes available. \n* **Confidentiality:** It addresses how confidential information will be handled during the JCA process and when reports are published. \n* **Data Protection:** It outlines rules for processing personal data related to the JCA process, ensuring compliance with EU data protection regulations.<\/p>\n**3. Main Provisions for Practical Use:**<\/p>\n* **Deadlines for Information Submission:** Health technology developers need to be aware of the strict deadlines for submitting information and data at various stages of the JCA process. \n* **Dossier Templates:** The regulation provides specific templates for the dossiers that health technology developers must submit. Adhering to these templates is crucial for ensuring that the dossier is complete and meets the requirements for assessment. \n* **Involvement of Experts and Stakeholders:** The regulation emphasizes the importance of involving individual experts and stakeholder organizations in the JCA process. This means that health technology developers may need to be prepared to address input from these groups. \n* **Confidentiality Requests:** Health technology developers need to be aware of the process for requesting confidential treatment of commercially sensitive information in the JCA reports. \n* **Updates and Re-Initiation:** The regulation outlines the procedures for updating JCAs when new evidence becomes available and for re-initiating JCAs that were previously discontinued. Health technology developers need to be aware of these procedures and be prepared to respond accordingly.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2074\"><\/p>\n<h3>Commission Implementing Regulation (EU) 2025\/2074 of 16\u00a0October 2025 granting a Union authorisation for the biocidal product family B. Braun Medical Propanol Family in accordance with Regulation (EU) No\u00a0528\/2012 of the European Parliament and of the Council<\/strong><\/h3>\n<\/a><\/p>\nThis is a Commission Implementing Regulation (EU) 2025\/2074, which grants a Union authorisation for the biocidal product family named \u2018B. Braun Medical Propanol Family\u2019. The product family is authorized for product-types 1, 2 and 4, which include human hygiene, disinfectants not for direct human\/animal use, and food\/feed area disinfection. The active substances in this product family are propan-1-ol and propan-2-ol. The authorisation is valid from 9 November 2025 until 31 October 2035.<\/p>\nThe regulation consists of two articles and two annexes. Article 1 grants the Union authorisation to B. Braun Medical AG for the biocidal product family \u2018B. Braun Medical Propanol Family\u2019, sets out the authorisation number and specifies the period of validity. Article 2 states when the regulation comes into force. Annex I outlines the terms and conditions of the authorisation, including the requirement for the authorisation holder to conduct a long-term storage stability test and submit the results to the Agency by 9 September 2026. Annex II provides a summary of the biocidal product characteristics for the \u2018B. Braun Medical Propanol Family\u2019, including administrative information, product family composition, hazard and precautionary statements, authorized uses, and general directions for use. The annex is structured into Meta SPCs (Summary of Product Characteristics), each detailing specific uses and compositions, and further breaks down into individual products within each Meta SPC, listing trade names, authorisation numbers, and specific compositions.<\/p>\nThe most important provisions for the use of this act are in Annex II, which describes in detail the authorized uses for each product type, including the target organisms, fields of use, application methods, rates, and frequency, categories of users, pack sizes, and packaging materials. It also specifies use-specific instructions, risk mitigation measures, first aid instructions, safe disposal instructions, and conditions for storage and shelf-life.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2084\"><\/p>\n<h3>Commission Regulation (EU) 2025\/2084 of 17\u00a0October 2025 amending Regulation (EC) No\u00a01333\/2008 of the European Parliament and of the Council as regards the use of quillaia extract (E 999) and Commission Regulation (EU) No\u00a0231\/2012 as regards the specifications for quillaia extract (E 999)<\/strong><\/h3>\n<\/a><\/p>\nThis is a description of Commission Regulation (EU) 2025\/2084 amending Regulation (EC) No 1333\/2008 and Regulation (EU) No 231\/2012 regarding the use and specifications of quillaia extract (E 999) as a food additive. The regulation updates the permitted uses of quillaia extract by authorizing its use as an emulsifier in flavorings and in solid and liquid food supplements (excluding those for infants and young children). It also revises the specifications for quillaia extract to align with current standards and recommendations from the European Food Safety Authority (EFSA).<\/p>\nThe regulation consists of 5 articles and 3 annexes. \n– Article 1 amends Annex II to Regulation (EC) No 1333\/2008, updating the permitted uses and maximum levels of quillaia extract in flavored drinks and cider\/perry, and adding new uses in solid and liquid food supplements. \n– Article 2 amends Annex III to Regulation (EC) No 1333\/2008, adding quillaia extract to the list of food additives and specifying its use in flavorings for various food categories with corresponding maximum levels. \n– Article 3 amends the Annex to Regulation (EU) No 231\/2012, replacing the existing specifications for quillaia extract with updated ones that include a more detailed definition, CAS number, minimum saponin content, reduced limits for toxic elements (arsenic, lead, mercury), and new limits for cadmium and calcium oxalate, as well as microbiological criteria. \n– Article 4 provides transitional rules, allowing the use of quillaia extract that was lawfully placed on the market before 9 May 2026 until stocks are exhausted, and allowing foods containing this quillaia extract to be placed on the market until their date of minimum durability or ‘use-by’ date. \n– Article 5 specifies the entry into force and application dates of the regulation.<\/p>\nThe most important provisions of this regulation are the expanded uses of quillaia extract (E 999) in flavorings and food supplements, and the updated, more stringent purity criteria for quillaia extract (E 999). The regulation also mandates that the maximum use levels of quillaia extract be expressed on a saponin basis. These changes ensure safer and more standardized use of the additive in the food industry.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:22025D2130\"><\/p>\n<h3>Decision No\u00a03\/2025 of the EU-Ukraine Association Committee in Trade Configuration of 14\u00a0October 2025 on the reduction and elimination of customs duties pursuant to Article\u00a029(4) of the Association Agreement between the European Union and the European Atomic Energy Community and their Member States, of the one part, and Ukraine, of the other part [2025\/2130]<\/strong><\/h3>\n<\/a><\/p>\nOkay, I will provide a detailed description of the provisions of this act.<\/p>\n**1. Essence of the Act:**<\/p>\n. Decision No. 3\/2025 of the EU-Ukraine Association Committee in Trade Configuration aims to reduce and eliminate customs duties between the European Union and Ukraine, as outlined in Article 29(4) of their Association Agreement. This decision introduces Annex I-E to the agreement, which supersedes previous tariff schedules and outlines each party’s commitments to reduce or eliminate customs duties on originating goods. The goal is to further enhance trade relations, considering Ukraine’s ongoing integration into the EU internal market and its accession negotiations. The decision also includes safeguard measures and production standards to ensure fair trade practices.<\/p>\n**2. Structure and Main Provisions:**<\/p>\n* **Article 1:** Inserts a new Annex I-E into the Association Agreement, which includes appendices detailing the reduction and elimination of customs duties. \n* **Article 2:** Specifies that for 2025, tariff rate quotas will be seven-twelfths of the quantities listed in Annex I-E. \n* **Article 3:** Mandates a review in 2028 to assess the level of reduction and elimination of customs duties, considering Ukraine’s progress in the accession process, with the possibility of further accelerating and broadening the scope of duty elimination. \n* **Article 4:** Confirms the authenticity of the decision in multiple languages. \n* **Article 5:** Sets the entry into force of the decision as the fifteenth day following its adoption.<\/p>\n**Annex I-E:**<\/p>\n* **Article 1:** States that each party will reduce or eliminate customs duties on originating goods of the other party according to Appendix A, superseding the rates in Annex I-A. If Appendix A is suspended, the rates in Annex I-A will apply. \n* **Article 2:** Requires Ukraine to align its legislation with EU legal acts listed in Appendix C by December 31, 2028, and to report annually on its progress. It also allows the EU to suspend preferences if Ukraine does not meet its obligations, with a mechanism for review and reintroduction of preferences. \n* **Article 3:** Allows either party to take safeguard measures if serious economic, societal, or environmental difficulties arise due to imports covered by the duty reductions, with a requirement for notification and consultations.<\/p>\n**Appendices:**<\/p>\n* **Appendix A:** Contains tariff schedules for both Ukraine and the EU, detailing specific goods and applicable duty rates, staging categories, and tariff rate quotas (TRQs). \n* **Appendix B:** Summarizes the aggregate quantities for TRQs for imports into the EU and Ukraine. \n* **Appendix C:** Lists EU production standards that Ukraine must align with, including directives and regulations related to animal welfare, plant protection products, and food and feed safety.<\/p>\n**Changes Compared to Previous Versions:**<\/p>\nThis decision introduces a new Annex I-E, which supersedes the schedules in Annex I-A of the original Association Agreement. This new annex broadens the scope of customs duty elimination and includes specific commitments from both parties. It also adds a mechanism for monitoring Ukraine’s alignment with EU production standards and allows for safeguard measures.<\/p>\n**3. Main Provisions for Use:**<\/p>\n* **Tariff Schedules (Appendix A):** Businesses need to carefully review the tariff schedules to understand the new duty rates and staging categories for specific goods. \n* **Production Standards (Appendix C):** Ukrainian producers should take note of the EU production standards listed, as compliance is required by the end of 2028 to maintain preferential access to the EU market. \n* **Safeguard Measures (Article 3 of Annex I-E):** Businesses should be aware of the conditions under which safeguard measures can be applied, potentially impacting trade flows. \n* **Tariff Rate Quotas (TRQs):** Pay close attention to the quantities and conditions for TRQs, as these determine the volume of goods that can be imported at reduced or zero duty rates. \n* **Reporting Obligations (Article 2 of Annex I-E):** Ukraine must report annually on its progress in regulatory alignment, which will be discussed in the Association Committee in Trade Configuration.<\/p>\n","protected":false},"excerpt":{"rendered":"Legal Analysis Analysis of EU Legislation 1. Anti-Dumping Duty on Steel Track Shoes from China The Commission has imposed a definitive anti-dumping duty of 62.5% on steel track shoes originating from China. This decision follows an investigation that confirmed Chinese companies were dumping these products on the EU market, harming local industry. Certain specialized steel…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"pmpro_default_level":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-12683","post","type-post","status-publish","format-standard","hentry","category-eu-legislation-detailed","pmpro-has-access"],"acf":{"patreon-level":0},"_links":{"self":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/posts\/12683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/comments?post=12683"}],"version-history":[{"count":0,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/posts\/12683\/revisions"}],"wp:attachment":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/media?parent=12683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/categories?post=12683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/tags?post=12683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

{"id":12683,"date":"2025-10-20T10:04:16","date_gmt":"2025-10-20T07:04:16","guid":{"rendered":"https:\/\/lexcovery.com\/2025\/10\/review-of-the-eu-legislation-for-20-10-2025\/"},"modified":"2025-10-20T10:04:16","modified_gmt":"2025-10-20T07:04:16","slug":"review-of-the-eu-legislation-for-20-10-2025","status":"publish","type":"post","link":"https:\/\/lexcovery.com\/en\/2025\/10\/review-of-the-eu-legislation-for-20-10-2025\/","title":{"rendered":"Review of the EU legislation for 20\/10\/2025"},"content":{"rendered":"

<\/p>\n

\nLegal Analysis<\/title> \n<\/head><\/p>\n<h5>Analysis of EU Legislation<\/h5>\n<h3>1. Anti-Dumping Duty on Steel Track Shoes from China<\/h3>\nThe Commission has imposed a definitive anti-dumping duty of 62.5% on steel track shoes originating from China. This decision follows an investigation that confirmed Chinese companies were dumping these products on the EU market, harming local industry. Certain specialized steel track shoes are excluded from this duty. For track chains containing these shoes, the duty applies to the value of the steel track shoes, provided they make up at least 31% of the chain’s total value. Provisional duties already collected will now be finalized.<\/p>\n<h3>2. Joint Clinical Assessments for Medical Devices<\/h3>\nThis regulation lays out the detailed procedures for how EU member states and the European Commission will exchange information during joint clinical assessments (JCAs) of medical devices. It covers the preparation, updating, and participation in these assessments, including templates for the assessments themselves. The health technology developers will be informed about the selection of their devices for JCA, and what information they need to provide.<\/p>\n<h3>3. Authorisation of ‘B. Braun Medical Propanol Family’ Biocidal Products<\/h3>\nThe European Commission has granted Union authorization for the biocidal product family ‘B. Braun Medical Propanol Family’, valid from November 2025 to October 2035. The authorization covers product-types 1, 2 and 4, which include human hygiene, disinfectants not for direct human\/animal use, and food\/feed area disinfection. The active substances in this product family are propan-1-ol and propan-2-ol. The authorisation holder must conduct a long-term storage stability test and submit the results to the Agency by September 2026.<\/p>\n<h3>4. Amendments Regarding Quillaia Extract (E 999) as a Food Additive<\/h3>\nThe EU has updated the rules for quillaia extract, a food additive. The regulation now allows its use as an emulsifier in flavorings and solid\/liquid food supplements (excluding those for infants and young children). The specifications for quillaia extract have also been revised with updated one that include a more detailed definition, CAS number, minimum saponin content, reduced limits for toxic elements (arsenic, lead, mercury), and new limits for cadmium and calcium oxalate, as well as microbiological criteria. Existing products lawfully on the market can still be sold until stocks run out or until their expiration date.<\/p>\n<h3>5. EU-Ukraine Association Committee Decision on Trade<\/h3>\nDecision No. 3\/2025 of the EU-Ukraine Association Committee in Trade Configuration introduces Annex I-E to the agreement. The goal is to further enhance trade relations, considering Ukraine’s ongoing integration into the EU internal market and its accession negotiations, by reducing and eliminating customs duties between the European Union and Ukraine. For 2025, tariff rate quotas will be seven-twelfths of the quantities listed in Annex I-E. Ukraine must align its legislation with EU legal acts listed in Appendix C by December 31, 2028, and to report annually on its progress.<\/p>\n<h3>Review of each of legal acts published today:<\/strong><\/h3>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2081\"><\/p>\n<h3>Commission Implementing Regulation (EU) 2025\/2081 of 17\u00a0October 2025 imposing a definitive anti-dumping duty and definitively collecting the provisional duty imposed on imports of steel track shoes originating in the People\u2019s Republic of China<\/strong><\/h3>\n<\/a><\/p>\nThis is a Commission Implementing Regulation imposing a definitive anti-dumping duty on imports of steel track shoes originating in the People\u2019s Republic of China. This regulation follows an anti-dumping investigation initiated after a complaint lodged by Duferco Travi e Profilati S.p.A. The Commission determined that steel track shoes from China were being dumped on the EU market, causing material injury to the Union industry. As a result, the regulation imposes a definitive anti-dumping duty of 62.5% on all imports of steel track shoes originating in China, with certain exceptions.<\/p>\nThe regulation is structured as follows: It begins by outlining the procedure, including the initiation of the investigation, registration of imports, and imposition of provisional measures. It then defines the product under investigation, the product concerned, and the like product. The regulation details the dumping calculation, including the determination of normal value, export price, and dumping margin. It assesses the injury to the Union industry, examining Union consumption, import volumes and prices, and the economic situation of the Union industry. The regulation also considers causation, the level of measures, and the Union interest. Finally, it sets out the definitive anti-dumping measures, including the duty rate and provisions for assembled products. Compared to the provisional regulation, this implementing regulation excludes certain cast steel track shoes from the scope of the anti-dumping duty and provides more detailed rules for the application of the duty to steel track shoes assembled in track chains.<\/p>\nSeveral provisions of this act are particularly important. First, the regulation imposes a definitive anti-dumping duty of 62.5% on imports of steel track shoes originating in China. Second, certain steel track shoes exceeding specific dimensions and lacking grousers are excluded from the duty. Third, for track chains containing steel track shoes, the regulation specifies that the anti-dumping duty applies to the value of the steel track shoes, with a minimum threshold of 31% of the track chain’s value. Finally, the regulation confirms that amounts secured by way of provisional anti-dumping duties will be definitively collected.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2086\"><\/p>\n<h3>Commission Implementing Regulation (EU) 2025\/2086 of 17\u00a0October 2025 laying down, pursuant to Regulation (EU)\u00a02021\/2282 on health technology assessment, procedural rules for the interaction during, exchange of information on, and participation in, the preparation and update of joint clinical assessments of medical devices and in vitro diagnostic medical devices at Union level, as well as templates for those joint clinical assessments<\/strong><\/h3>\n<\/a><\/p>\nHere’s a breakdown of the Commission Implementing Regulation (EU) 2025\/2086:<\/p>\n**1. Essence of the Act:**<\/p>\nThis regulation establishes the detailed procedures for how the Member States and the European Commission will interact and exchange information when conducting joint clinical assessments (JCAs) of medical devices and in vitro diagnostic medical devices within the European Union. It outlines the steps for preparing, updating, and participating in these joint assessments, including templates for the assessments themselves. The goal is to streamline the process, avoid duplication of effort, and ensure that medical devices are evaluated consistently across the EU.<\/p>\n**2. Structure and Main Provisions:**<\/p>\nThe regulation is structured around the procedural aspects of joint clinical assessments for medical devices, focusing on interactions and information exchange. Key provisions include:<\/p>\n* **Information Flow:** It details how the Coordination Group for Health Technology Assessment, the European Commission (acting as the secretariat), notified bodies, expert panels, health technology developers, and individual experts will exchange information during the JCA process. \n* **Health Technology Developer Involvement:** It specifies when and how health technology developers are informed about the selection of their devices for JCA, and what information they need to provide. \n* **Expert Selection:** It outlines the process for selecting individual experts to participate in JCAs, emphasizing the need for diverse expertise and conflict of interest management. \n* **Assessment Scope and Dossier Submission:** It sets deadlines and procedures for finalizing the assessment scope (the specific questions the JCA will address) and for health technology developers to submit the necessary data and documentation. \n* **Report Templates:** It includes templates for the dossiers that health technology developers must submit, as well as for the joint clinical assessment reports and summary reports. \n* **Timelines:** It establishes specific deadlines for various steps in the JCA process, from finalizing the assessment scope to completing the draft reports. \n* **Re-initiation and Updates:** It provides rules for re-initiating a JCA if it was initially discontinued, and for updating a JCA when new evidence becomes available. \n* **Confidentiality:** It addresses how confidential information will be handled during the JCA process and when reports are published. \n* **Data Protection:** It outlines rules for processing personal data related to the JCA process, ensuring compliance with EU data protection regulations.<\/p>\n**3. Main Provisions for Practical Use:**<\/p>\n* **Deadlines for Information Submission:** Health technology developers need to be aware of the strict deadlines for submitting information and data at various stages of the JCA process. \n* **Dossier Templates:** The regulation provides specific templates for the dossiers that health technology developers must submit. Adhering to these templates is crucial for ensuring that the dossier is complete and meets the requirements for assessment. \n* **Involvement of Experts and Stakeholders:** The regulation emphasizes the importance of involving individual experts and stakeholder organizations in the JCA process. This means that health technology developers may need to be prepared to address input from these groups. \n* **Confidentiality Requests:** Health technology developers need to be aware of the process for requesting confidential treatment of commercially sensitive information in the JCA reports. \n* **Updates and Re-Initiation:** The regulation outlines the procedures for updating JCAs when new evidence becomes available and for re-initiating JCAs that were previously discontinued. Health technology developers need to be aware of these procedures and be prepared to respond accordingly.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2074\"><\/p>\n<h3>Commission Implementing Regulation (EU) 2025\/2074 of 16\u00a0October 2025 granting a Union authorisation for the biocidal product family B. Braun Medical Propanol Family in accordance with Regulation (EU) No\u00a0528\/2012 of the European Parliament and of the Council<\/strong><\/h3>\n<\/a><\/p>\nThis is a Commission Implementing Regulation (EU) 2025\/2074, which grants a Union authorisation for the biocidal product family named \u2018B. Braun Medical Propanol Family\u2019. The product family is authorized for product-types 1, 2 and 4, which include human hygiene, disinfectants not for direct human\/animal use, and food\/feed area disinfection. The active substances in this product family are propan-1-ol and propan-2-ol. The authorisation is valid from 9 November 2025 until 31 October 2035.<\/p>\nThe regulation consists of two articles and two annexes. Article 1 grants the Union authorisation to B. Braun Medical AG for the biocidal product family \u2018B. Braun Medical Propanol Family\u2019, sets out the authorisation number and specifies the period of validity. Article 2 states when the regulation comes into force. Annex I outlines the terms and conditions of the authorisation, including the requirement for the authorisation holder to conduct a long-term storage stability test and submit the results to the Agency by 9 September 2026. Annex II provides a summary of the biocidal product characteristics for the \u2018B. Braun Medical Propanol Family\u2019, including administrative information, product family composition, hazard and precautionary statements, authorized uses, and general directions for use. The annex is structured into Meta SPCs (Summary of Product Characteristics), each detailing specific uses and compositions, and further breaks down into individual products within each Meta SPC, listing trade names, authorisation numbers, and specific compositions.<\/p>\nThe most important provisions for the use of this act are in Annex II, which describes in detail the authorized uses for each product type, including the target organisms, fields of use, application methods, rates, and frequency, categories of users, pack sizes, and packaging materials. It also specifies use-specific instructions, risk mitigation measures, first aid instructions, safe disposal instructions, and conditions for storage and shelf-life.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:32025R2084\"><\/p>\n<h3>Commission Regulation (EU) 2025\/2084 of 17\u00a0October 2025 amending Regulation (EC) No\u00a01333\/2008 of the European Parliament and of the Council as regards the use of quillaia extract (E 999) and Commission Regulation (EU) No\u00a0231\/2012 as regards the specifications for quillaia extract (E 999)<\/strong><\/h3>\n<\/a><\/p>\nThis is a description of Commission Regulation (EU) 2025\/2084 amending Regulation (EC) No 1333\/2008 and Regulation (EU) No 231\/2012 regarding the use and specifications of quillaia extract (E 999) as a food additive. The regulation updates the permitted uses of quillaia extract by authorizing its use as an emulsifier in flavorings and in solid and liquid food supplements (excluding those for infants and young children). It also revises the specifications for quillaia extract to align with current standards and recommendations from the European Food Safety Authority (EFSA).<\/p>\nThe regulation consists of 5 articles and 3 annexes. \n– Article 1 amends Annex II to Regulation (EC) No 1333\/2008, updating the permitted uses and maximum levels of quillaia extract in flavored drinks and cider\/perry, and adding new uses in solid and liquid food supplements. \n– Article 2 amends Annex III to Regulation (EC) No 1333\/2008, adding quillaia extract to the list of food additives and specifying its use in flavorings for various food categories with corresponding maximum levels. \n– Article 3 amends the Annex to Regulation (EU) No 231\/2012, replacing the existing specifications for quillaia extract with updated ones that include a more detailed definition, CAS number, minimum saponin content, reduced limits for toxic elements (arsenic, lead, mercury), and new limits for cadmium and calcium oxalate, as well as microbiological criteria. \n– Article 4 provides transitional rules, allowing the use of quillaia extract that was lawfully placed on the market before 9 May 2026 until stocks are exhausted, and allowing foods containing this quillaia extract to be placed on the market until their date of minimum durability or ‘use-by’ date. \n– Article 5 specifies the entry into force and application dates of the regulation.<\/p>\nThe most important provisions of this regulation are the expanded uses of quillaia extract (E 999) in flavorings and food supplements, and the updated, more stringent purity criteria for quillaia extract (E 999). The regulation also mandates that the maximum use levels of quillaia extract be expressed on a saponin basis. These changes ensure safer and more standardized use of the additive in the food industry.<\/p>\n<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/AUTO\/?uri=CELEX:22025D2130\"><\/p>\n<h3>Decision No\u00a03\/2025 of the EU-Ukraine Association Committee in Trade Configuration of 14\u00a0October 2025 on the reduction and elimination of customs duties pursuant to Article\u00a029(4) of the Association Agreement between the European Union and the European Atomic Energy Community and their Member States, of the one part, and Ukraine, of the other part [2025\/2130]<\/strong><\/h3>\n<\/a><\/p>\nOkay, I will provide a detailed description of the provisions of this act.<\/p>\n**1. Essence of the Act:**<\/p>\n. Decision No. 3\/2025 of the EU-Ukraine Association Committee in Trade Configuration aims to reduce and eliminate customs duties between the European Union and Ukraine, as outlined in Article 29(4) of their Association Agreement. This decision introduces Annex I-E to the agreement, which supersedes previous tariff schedules and outlines each party’s commitments to reduce or eliminate customs duties on originating goods. The goal is to further enhance trade relations, considering Ukraine’s ongoing integration into the EU internal market and its accession negotiations. The decision also includes safeguard measures and production standards to ensure fair trade practices.<\/p>\n**2. Structure and Main Provisions:**<\/p>\n* **Article 1:** Inserts a new Annex I-E into the Association Agreement, which includes appendices detailing the reduction and elimination of customs duties. \n* **Article 2:** Specifies that for 2025, tariff rate quotas will be seven-twelfths of the quantities listed in Annex I-E. \n* **Article 3:** Mandates a review in 2028 to assess the level of reduction and elimination of customs duties, considering Ukraine’s progress in the accession process, with the possibility of further accelerating and broadening the scope of duty elimination. \n* **Article 4:** Confirms the authenticity of the decision in multiple languages. \n* **Article 5:** Sets the entry into force of the decision as the fifteenth day following its adoption.<\/p>\n**Annex I-E:**<\/p>\n* **Article 1:** States that each party will reduce or eliminate customs duties on originating goods of the other party according to Appendix A, superseding the rates in Annex I-A. If Appendix A is suspended, the rates in Annex I-A will apply. \n* **Article 2:** Requires Ukraine to align its legislation with EU legal acts listed in Appendix C by December 31, 2028, and to report annually on its progress. It also allows the EU to suspend preferences if Ukraine does not meet its obligations, with a mechanism for review and reintroduction of preferences. \n* **Article 3:** Allows either party to take safeguard measures if serious economic, societal, or environmental difficulties arise due to imports covered by the duty reductions, with a requirement for notification and consultations.<\/p>\n**Appendices:**<\/p>\n* **Appendix A:** Contains tariff schedules for both Ukraine and the EU, detailing specific goods and applicable duty rates, staging categories, and tariff rate quotas (TRQs). \n* **Appendix B:** Summarizes the aggregate quantities for TRQs for imports into the EU and Ukraine. \n* **Appendix C:** Lists EU production standards that Ukraine must align with, including directives and regulations related to animal welfare, plant protection products, and food and feed safety.<\/p>\n**Changes Compared to Previous Versions:**<\/p>\nThis decision introduces a new Annex I-E, which supersedes the schedules in Annex I-A of the original Association Agreement. This new annex broadens the scope of customs duty elimination and includes specific commitments from both parties. It also adds a mechanism for monitoring Ukraine’s alignment with EU production standards and allows for safeguard measures.<\/p>\n**3. Main Provisions for Use:**<\/p>\n* **Tariff Schedules (Appendix A):** Businesses need to carefully review the tariff schedules to understand the new duty rates and staging categories for specific goods. \n* **Production Standards (Appendix C):** Ukrainian producers should take note of the EU production standards listed, as compliance is required by the end of 2028 to maintain preferential access to the EU market. \n* **Safeguard Measures (Article 3 of Annex I-E):** Businesses should be aware of the conditions under which safeguard measures can be applied, potentially impacting trade flows. \n* **Tariff Rate Quotas (TRQs):** Pay close attention to the quantities and conditions for TRQs, as these determine the volume of goods that can be imported at reduced or zero duty rates. \n* **Reporting Obligations (Article 2 of Annex I-E):** Ukraine must report annually on its progress in regulatory alignment, which will be discussed in the Association Committee in Trade Configuration.<\/p>\n","protected":false},"excerpt":{"rendered":"Legal Analysis Analysis of EU Legislation 1. Anti-Dumping Duty on Steel Track Shoes from China The Commission has imposed a definitive anti-dumping duty of 62.5% on steel track shoes originating from China. This decision follows an investigation that confirmed Chinese companies were dumping these products on the EU market, harming local industry. Certain specialized steel…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"pmpro_default_level":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-12683","post","type-post","status-publish","format-standard","hentry","category-eu-legislation-detailed","pmpro-has-access"],"acf":{"patreon-level":0},"_links":{"self":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/posts\/12683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/comments?post=12683"}],"version-history":[{"count":0,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/posts\/12683\/revisions"}],"wp:attachment":[{"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/media?parent=12683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/categories?post=12683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lexcovery.com\/en\/wp-json\/wp\/v2\/tags?post=12683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}